A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
ClinicalTrials.gov · NCT00734474 · Registry updated: 2015-04-20
- Condition / research focus
- Diabetes Mellitus, Type 2
- Sponsor
- Eli Lilly and Company
- Countries with listed sites
- Canada · France · Germany · India · Mexico · Poland · Puerto Rico · Romania · Russia · South Korea · Spain · Taiwan · United States
- Registry dates and results
- Start: 2008-08. Completion: 2012-07 (may be estimated). Results are posted in this registry.
Products and interventions (5)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- LY2189265 (drug) — also listed as: Dulaglutide, Trulicity
- Sitagliptin (drug)
- Placebo solution (drug)
- Placebo tablet (drug)
- Metformin (drug)
Where the study takes place — 99 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

